Sleep disturbances are commonly encountered in people with advanced Parkinson's disease (PD). In these stages, levodopa–carbidopa intestinal gel (LCIG) is recommended for improving motor symptoms, some non-motor dysfunctions, and quality of life in these patients. This study aimed to assess the effects of LCIG on sleep in PD in a longitudinal study.
An open-label observational study in patients with advanced PD undergoing LCIG treatment was carried out.
In total, 10 consecutive advanced people with PD were evaluated at the baseline and after 6 months and 1 year, respectively, of LCIG infusion. Sleep parameters were assessed with several validated scales. We assessed the evolution of sleep parameters under LCIG infusion over time and the effects on sleep quality.
Significant improvement following LCIG was observed in PSQI total score (
LCIG infusion demonstrated beneficial effects on sleep parameters and sleep quality, which were constant over time for up to 12 months.